Joint development from problem statement to qualified product — isotherms, trial batches and pilot data, with the intellectual property arrangement agreed at the start.
The specification is the deliverable; the sample is only evidence for it.
A trial batch that works once has proved very little. The programme is designed to establish which variables actually control the result, how wide each can range before the result moves, and whether the route survives the transition from laboratory equipment to plant equipment. Those three answers are what turn a promising sample into something that can be ordered again next year.
6–12
weeks to first trial batch
Typical elapsed time from characterisation to material for testing.
Each stage ends in a decision, not just a report.
The requirement is written as a measurable target with a test method attached. Without that, the programme has no way to establish whether it has succeeded.
Candidate materials and routes are evaluated against real samples at laboratory scale, narrowing the field quickly and cheaply before capital time is committed.
The leading candidates are made at pilot scale and tested under conditions that resemble the real process, including the failure modes that only appear at scale.
The result is written up as a specification with a control plan, released against a retained standard, and transferred into routine manufacture.
The format is chosen against the size of the question and the commitment behind it.
Laboratory scale · short cycle
Candidate materials screened against the target on real samples, to establish quickly whether a viable route exists before larger commitments are made.
Pilot scale · staged
A staged programme with defined gates, taking a screened candidate through trial batches, pilot production and a documented specification.
Shared programme · defined IP
A longer arrangement where both sides contribute technical work and the ownership of the outcome is defined in the agreement rather than assumed.
These are agreed before the first sample changes hands.
From characterisation to a qualified specification, depending on how many variables have to be resolved and how long the testing cycle takes.
Scaled to what the testing actually requires. Larger trials cost more and prove more; the step size is agreed rather than defaulted.
A mutual non-disclosure agreement is executed before technical detail is exchanged, covering samples, data and the existence of the programme.
Ownership of the resulting formulation, process knowledge and any filing is written into the agreement before development work begins.
Both sides test to the same method against the same standard, since most disputed results turn out to be method differences.
Each stage ends in a decision to proceed, revise or stop, with the data behind it recorded so the reasoning survives staff changes.
With a confidentiality agreement, then a technical conversation to turn the requirement into a measurable target with a test method attached. Representative samples follow, and a short screening stage establishes whether a viable route exists before larger commitments are made.
Whatever the agreement says, which is written before development work begins. Arrangements range from full customer ownership of an exclusive grade through to shared rights where both sides contribute substantial technical work. It is settled first precisely because it is difficult to settle later.
Six to twelve weeks to a first trial batch in straightforward cases, and considerably longer where the testing cycle is slow, regulatory qualification is involved, or field trials are required. The programme is staged so the timeline is visible at each gate.
It depends on the scale of trials and the length of the programme. Screening work at laboratory scale is usually absorbed against the prospect of supply; extended pilot programmes and dedicated plant time are quoted, and the basis is agreed before the stage begins.
The gate structure exists so that a programme can be stopped early and cheaply when the data does not support continuing. The characterisation work and the negative results still tell you which routes not to pursue, and they remain covered by the confidentiality agreement.
Send the requirement, a representative sample and the target the material has to clear, and we will come back with a scope, a staged timeline and the terms to sign.
